Laboratory Services

Antimullerian Hormone, Serum

Print this page

Updated Test Information:

Test Description
Antimullerian Hormone, Serum
Synonym(s)

Mullerian inhibiting factor (MIF); Mullerian-inhibiting hormone (MIH); Mullerian-inhibiting substance (MIS)

Test ID
AMH1
General Information

Useful For:



  • Assessing ovarian status, including ovarian reserve and ovarian responsiveness, as part of an evaluation for infertility and assisted reproduction protocols

  • Assessment of menopausal status, including premature ovarian failure

  • Evaluation of infants with ambiguous genitalia and other intersex conditions

  • Evaluating testicular function in infants and children

  • Monitoring patients with antimullerian hormone-secreting ovarian granulosa cell tumors

Specimen Type

Serum

Specimen Requirements

  • Preferred: Serum Gel

  • Acceptable: Red Top

Minimum Sample Volume

0.75 mL



Stability

  • Refrigerated (preferred): 7 days

  • Frozen: 180 days

  • Ambient: 7 days

Unacceptable Specimen Conditions

  • Gross hemolysis: acceptable to 1000 mg/dL

  • Gross icterus: acceptable to 66 mg/dL

Limitations

  • Interference was observed at biotin concentrations above 30 ng/mL. Samples should not be taken from patients receiving therapy with high biotin doses until at least 12 hours following the last biotin administration.

  • The following drugs may interfere with this test: Cetrotide, Ovitrelle, Endometrin and Follistatin: do not use this test to analyze samples from patients who have received 1 or more of these products within 1 to 2 weeks of testing.

  • There is no high-dose hook effect at AMH concentrations up to 1400 ng/mL.

  • In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. The laboratory should be alerted if the result does not correlate with the clinical presentation.

  • For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

  • AMH immunoassays are not standardized and values obtained with different assay methods or kits may be different and cannot be used interchangeably.

  • If using as a tumor marker, test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

Methodology

Electrochemiluminescent Immunoassay (ECLIA)

Estimated TAT

1-3 days

Testing Schedule

Monday - Saturday

Retention

3 months

CPT Code(s)

83520

Reference Range
Males: Age (years) Range (ng/mL) Females: Age (years) Range (ng/mL)
< 2 18 - 283 < 3 0.11 - 4.20
2 - 12 8.9 - 109 3 - 6 0.21 - 4.90
> 12 < 13 7 - 11 0.36 - 5.90
    12 - 14 0.49 - 6.90
    15 - 19 0.62 - 7.80
    20 - 24 1.20 - 12.00
    25 - 29 0.89 - 9.90
    30 - 34 0.58 - 8.10
    35 - 39 0.15 - 7.50
    40 - 44 0.03 - 5.50
    45 - 50 0.00 - 2.60
    51 - 55 0.00 - 0.88
    > 55 0.00 - 0.03

 

Performing Lab

Mayo Clinic

Additional Information